Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and ACADIA Pharmaceuticals Inc.

Comparative SG&A Analysis: ACADIA vs. Alpine Immune Sciences

__timestampACADIA Pharmaceuticals Inc.Alpine Immune Sciences, Inc.
Wednesday, January 1, 2014327480002287709
Thursday, January 1, 2015908040006844000
Friday, January 1, 20161864560008586000
Sunday, January 1, 20172550620006079000
Monday, January 1, 20182657580008362000
Tuesday, January 1, 20193256380009467000
Wednesday, January 1, 202038866100010899000
Friday, January 1, 202139602800014560000
Saturday, January 1, 202236909000017968000
Sunday, January 1, 202340246600022222000
Loading chart...

Data in motion

Cost Management Insights: A Comparative Analysis

In the ever-evolving pharmaceutical landscape, effective cost management is crucial for sustained growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: ACADIA Pharmaceuticals Inc. and Alpine Immune Sciences, Inc., from 2014 to 2023.

ACADIA Pharmaceuticals has seen a steady increase in SG&A expenses, peaking at approximately $402 million in 2023, marking a 23% rise from 2014. This trend reflects their aggressive market expansion and investment in operational capabilities. In contrast, Alpine Immune Sciences, Inc. has maintained a more conservative approach, with expenses growing from around $2.3 million in 2014 to $22 million in 2023, a tenfold increase.

This comparative insight highlights the diverse strategies employed by these companies in managing operational costs, offering valuable lessons in balancing growth with financial prudence.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025